Revolution Medicines, Inc. Q4 FY2023 earnings call

Key Points

• 2023 was transformative: Disclosed preliminary clinical profiles of RMC-6236 and RMC-6291 in Phase 1/1b trials, dosed first patient in RMC-9805 trial.
• Strong balance sheet post-EQRx acquisition with ~$1.1B net cash proceeds.
• 2024 priorities:
  • Propel RMC-6236 into first pivotal trial for lung and pancreatic cancer.
  • Expand RMC-6236 to other RAS mutations (G13X, Q61X) and tumor types (colorectal, melanoma, gynecology).
  • Qualify RMC-6291 and RMC-9805 for late-stage development, including initiating doublet trials for RMC-6291 with RMC-6236.

There are no distinct product segments with revenue contributions detailed. The company focuses on its RAS inhibitor pipeline, with financials related to operating expenses, revenue from collaborations, and cash position.

Financial Guidance

• Full year 2024 GAAP net loss expected to be between $480 million and $520 million, including non-cash stock-based compensation expense of $70 million to $80 million. Increase in loss due to increased expenses from ongoing clinical development programs.

Risks

• Forward-looking statements subject to assumptions, risks, and uncertainties. Actual results may differ materially from forward-looking statements. Potential challenges in clinical trial outcomes, regulatory approvals, and commercialization of RAS inhibitors.

Q: On the combinations with pembro for 6291 and 6236, what would you like to see on early data to move into pivotal development?

A: Primarily validate safety, as combined hepatotoxicity has been a challenge with other RAS inhibitors, so establishing a safe profile to support first-line development.

Q: Do you talk about the potential for combining 9805 with 6236?

A: We haven't said much, but the 6291plus 6236 combination is a key test case; if it carries through, it would encourage combining other mutant selective inhibitors with 6236, including 9805.

Q: How much more data do you need to support initiation of Phase 3 for 6236?

A: Looking for mature PFS assessment and FDA input for finalizing trial design with statistical power.

Q: On planned combination studies with 6236 in frontline pancreatic, what are the gating steps?

A: Looking for adequate tolerability and efficacy signal in combination setting to warrant frontline pursuit; Dr. Lin would comment on specific requirements.

Q: What should we expect from initial KRAS combo data later this year?

A: First check safety, then look for clinical activity signals like frequency, depth, or durability of response in combination.